Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently recruiting participants for a Phase 3 clinical study titled ‘A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)’. The study aims to compare progression-free survival and overall survival between two treatment groups, highlighting its significance in advancing treatment options for this type of lung cancer.
The study tests two interventions: Sotorasib combined with carboplatin and pemetrexed, and Pembrolizumab combined with carboplatin and pemetrexed. Sotorasib is administered orally, while Pembrolizumab is given intravenously, both targeting advanced lung cancer.
This interventional study is randomized with a parallel assignment model, focusing on treatment as the primary purpose. It is open-label, meaning no masking is involved, allowing both researchers and participants to know the treatment being administered.
The study began on November 16, 2023, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
The outcome of this study could significantly impact Amgen’s stock performance and investor sentiment, as successful results may enhance the company’s competitive position in the oncology market. Investors should monitor this study’s progress, considering the broader industry context and potential shifts in treatment standards.
The study is ongoing, with further details available on the ClinicalTrials portal.